Author

D. Roden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Swarbrick· 2 shared C.-L. Chan· 2 shared K. Harvey· 2 shared S. Z. Wu· 2 shared A. Anderson· 1 shared A. McFarland· 1 shared A. S. Cazet· 1 shared B. L. Elsworth· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Swarbrick

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integration of single-cell RNA and protein data identifies novel clinically-relevant lymphocyte phenotypes in breast cancers

G. Al-Eryani, N. Bartonicek, C.-L. Chan, A. Anderson, K. Harvey, S. Z. Wu, D. Roden, T. Wang, J. Reeves, B. Z. Yeung, E. Masle-Farquhar, C. C. Goodnow, C. Ma, T. G. Phan, J. Lundeberg, , A. Swarbrick

The paper integrates single-cell RNA and protein data from breast cancer samples to identify novel lymphocyte phenotypes and their clinical relevance.

bioRxiv · May 31, 2022 · PreprintImmunology

Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer

A. S. Cazet, M. N. Hui, B. L. Elsworth, S. Z. Wu, D. Roden, C.-L. Chan, J. N. Skhinas, R. Collot, J. Yang, K. Harvey, M. Z. Johan, C. Cooper, R. Nair, D. Herrmann, A. McFarland, , A. Swarbrick

This study identifies Hedgehog signaling to cancer-associated fibroblasts as a driver of cancer stem cell plasticity and chemoresistance in TNBC, showing that targeting this pathway with smoothened inhibitors improves survival in preclinical models and clinical trials.

bioRxiv · Nov 8, 2017Cancer Biology